Physician profile
David A Keller
NPI 1467417733
$19,243.41
in general payments reported to CMS, 2019-2025
57 companies · $8,587 in 2025
The $8,587 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,867 · 2020: $625 · 2021: $1,866 · 2022: $1,960 · 2023: $2,270 · 2024: $2,070 · 2025: $8,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,708 · Consulting Fee: $5,250 · Travel and Lodging: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,708.09 |
| Consulting Fee | $5,250.00 |
| Travel and Lodging | $968.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $6,941.92 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,488.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,255.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,236.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $1,234.54 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Amgen INC. | $609.95 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $607.33 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $307.08 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $296.89 | 2022-2025 | Auvelity, Symbravo |
| Sanofi Pasteur INC. | $281.20 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $255.88 | 2021-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $255.76 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $246.92 | 2019-2023 | |
| Amarin Pharma, INC. | $239.75 | 2019-2022 | |
| Astellas Pharma US INC | $230.79 | 2019-2025 | Veozah |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $218.36 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $212.25 | 2021-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $211.24 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $210.30 | 2021-2024 | Glassia, Trintellix |
| Merck Sharp & Dohme LLC | $199.43 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbott Laboratories | $172.38 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Dexcom, INC. | $161.69 | 2021-2025 | Dexcom G6 Transmitter |
| Prodigy Surgical Distribution, INC. | $160.32 | 2025 | |
| Eisai INC. | $154.39 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $143.43 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.90 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Genzyme Corporation | $130.00 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $127.27 | 2019-2025 | Zoryve |
| Lundbeck LLC | $104.00 | 2023-2024 | Rexulti |
| Genentech USA, INC. | $102.22 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.07 | 2023-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.79 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $83.71 | 2022 | |
| Cequr Corporation | $82.53 | 2024-2025 | Cequr Simplicity |
| Sunovion Pharmaceuticals INC. | $82.09 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $81.58 | 2020-2023 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $77.39 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $75.26 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $73.37 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $73.29 | 2019-2022 | |
| Ibsa Pharma INC. | $64.53 | 2022-2023 | Tirosint, Licart |
| Daiichi Sankyo INC. | $54.90 | 2019-2021 | |
| Allergan, INC. | $46.27 | 2020 | |
| Clarus Therapeutics INC. | $45.60 | 2021 | |
| Seqirus USA INC | $44.99 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Xeris Pharmaceuticals, INC. | $30.93 | 2023 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $28.74 | 2023 | Lyvispah |
| Impel Pharmaceuticals INC. | $24.50 | 2022 | |
| Boston Scientific Corporation | $22.85 | 2024 | Wavewriter Alpha Prime 16 |
| Phadia US INC. | $20.12 | 2025 | Immunocap |
| Ironwood Pharmaceuticals, INC | $18.11 | 2024 | |
| Viatris Specialty LLC | $16.76 | 2025 | Yupelri |
| Ultragenyx Pharmaceutical INC. | $16.74 | 2023 | Crysvita |
| Medtronic, INC. | $14.53 | 2023 | Inpen Smart Insulin Delivery System |
| Smith+Nephew, INC. | $14.24 | 2022 | |
| Tolmar, INC. | $13.08 | 2023 | |
| Avanir Pharmaceuticals, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.